1. Search Result
Search Result
Results for "

COMT+Inhibitors

" in MedChemExpress (MCE) Product Catalog:

33

Inhibitors & Agonists

3

Natural
Products

10

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125339

    COMT Neurological Disease
    Ro 41-0960 is a selective catechol-O-methyltransferase(COMT) inhibitor .
    Ro 41-0960
  • HY-100562

    5-HT Receptor COMT Neurological Disease
    Flopropione is a 5-HT receptor antagonist and also a catechol-o-methyltransferase (COMT) inhibitor . Flopropione also as an antispasmodic agent .
    Flopropione
  • HY-B1473A
    Serotonin
    Maximum Cited Publications
    20 Publications Verification

    5-Hydroxytryptamine; 5-HT

    5-HT Receptor COMT Endogenous Metabolite Neurological Disease
    Serotonin is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist. Serotonin is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM.
    Serotonin
  • HY-B1473
    Serotonin hydrochloride
    Maximum Cited Publications
    20 Publications Verification

    5-Hydroxytryptamine hydrochloride; 5-HT hydrochloride

    5-HT Receptor COMT Endogenous Metabolite Neurological Disease
    Serotonin (5-Hydroxytryptamine) hydrochloride is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist. Serotonin hydrochloride is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM.
    Serotonin hydrochloride
  • HY-139089

    COMT Metabolic Disease
    (Z)-Entacapone is a metabolite of the catechol-O-methyltransferase (COMT) inhibitor Entacapone (HY-14280). It is also a potential impurity found in commercial preparations of Entacapone and a degradant of Entacapone formed by UV light exposure.
    (Z)-Entacapone
  • HY-14896
    Opicapone
    3 Publications Verification

    BIA 9-1067

    COMT Neurological Disease
    Opicapone (BIA 9-1067) is a potent third-generation catechol-O-methyltransferase (COMT) inhibitor for the research of Parkinson's disease and motor fluctuations. Opicapone decreases the ATP content of the cells with an IC50 of 98 μM .
    Opicapone
  • HY-B1473AS

    5-Hydroxytryptamine-d4; 5-HT-d4

    Isotope-Labeled Compounds 5-HT Receptor COMT Endogenous Metabolite Neurological Disease
    Serotonin-d4 is deuterium labeled Serotonin. Serotonin is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist. Serotonin is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM.
    Serotonin-d4
  • HY-106842

    OR-462

    COMT Neurological Disease Inflammation/Immunology
    Nitecapone (OR-462) is an orally active and short-acting catechol-O-methyltransferase (COMT) inhibitor with gastroprotective and antioxidant properties. Nitecapone (OR-462) scavenges reactive oxygen and nitric radicals and prevents lipid peroxidation .
    Nitecapone
  • HY-169611

    5-Hydroxytryptamine maleate; 5-HT maleate

    5-HT Receptor COMT Neurological Disease
    Serotonin hydrogen maleate is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist. Serotonin hydrogen maleate is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM .
    Serotonin maleate
  • HY-168154

    COMT Cancer
    COMT-IN-2 (compund 9) is the potent COMT inhibitor, showing selective inhibition of brain (IC50=24 nM) and liver (IC50=81 nM) MB-COMT compared to the liver S-COMT (IC50=620 nM) isoform .
    COMT-IN-2
  • HY-106405

    BIA 3-202

    COMT Metabolic Disease
    Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease .
    Nebicapone
  • HY-14896R

    BIA 9-1067 (Standard)

    Reference Standards COMT Neurological Disease
    Opicapone (Standard) is the analytical standard of Opicapone. This product is intended for research and analytical applications. Opicapone (BIA 9-1067) is a potent third-generation catechol-O-methyltransferase (COMT) inhibitor for the research of Parkinson's disease and motor fluctuations. Opicapone decreases the ATP content of the cells with an IC50 of 98 μM .
    Opicapone (Standard)
  • HY-W704878

    Isotope-Labeled Compounds COMT Metabolic Disease
    (Z)-Entacapone-d10-1 is the deuterium labeled (Z)-Entacapone (HY-139089). (Z)-Entacapone is a metabolite of the catechol-O-methyltransferase (COMT) inhibitor Entacapone (HY-14280). It is also a potential impurity found in commercial preparations of Entacapone and a degradant of Entacapone formed by UV light exposure.
    (Z)-Entacapone-d10-1
  • HY-B1473S1

    5-Hydroxytryptamine-13C2,15N hydrochloride; 5-HT-13C2,15N hydrochloride

    Isotope-Labeled Compounds 5-HT Receptor COMT Endogenous Metabolite Neurological Disease
    Serotonin- 13C2, 15N hydrochloride is the 13C- and 15N-labeled Serotonin hydrochloride (HY-B1473). Serotonin hydrochloride is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist. Serotonin hydrochloride is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM .
    Serotonin-13C2,15N hydrochloride
  • HY-B1473S

    5-Hydroxytryptamine-d4 hydrochloride; 5-HT-d4 hydrochloride

    Isotope-Labeled Compounds 5-HT Receptor Endogenous Metabolite COMT Others
    Serotonin-d4 (5-Hydroxytryptamine-d4) hydrochloride is the deuterium labeled Serotonin (hydrochloride) (HY-B1473) . Serotonin (5-Hydroxytryptamine) hydrochloride is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist. Serotonin hydrochloride is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM .
    Serotonin-d4 hydrochloride
  • HY-106405R

    BIA 3-202 (Standard)

    Reference Standards COMT Metabolic Disease
    Nebicapone (Standard) is the analytical standard of Nebicapone. This product is intended for research and analytical applications. Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease .
    Nebicapone (Standard)
  • HY-B1473S2

    5-Hydroxytryptamine-13C,D4; 5-HT-13C,D4

    Isotope-Labeled Compounds 5-HT Receptor COMT Endogenous Metabolite Neurological Disease
    Serotonin- 13C,D4 (5-Hydroxytryptamine-13C,D4) is a 13C- and deuterated labeled Serotonin (HY-B1473A). Serotonin is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist. Serotonin is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM .
    Serotonin-13C,D4
  • HY-17406
    Tolcapone
    2 Publications Verification

    Ro 40-7592

    COMT Amyloid-β Apoptosis Reactive Oxygen Species (ROS) Neurological Disease Cancer
    Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor with an IC50of 773 nM. Tolcapone can inhibits α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone can cause oxidative stress and induce cancer cells apoptosis and ROS production. Tolcapone can be used for the researches of cancer and neurological disease, such as Parkinson disease and neuroblastoma .
    Tolcapone
  • HY-151388

    Monoamine Oxidase COMT Neurological Disease
    hMAO-B/MB-COMT-IN-1 is a dual MAO-B/MB-COMT inhibitor (IC50s: 2.5 μΜ for hMAO-B, 3.84 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-1 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-1 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD) .
    hMAO-B/MB-COMT-IN-1
  • HY-151390

    Monoamine Oxidase COMT Neurological Disease
    hMAO-B/MB-COMT-IN-2 is a dual MAO-B/MB-COMT inhibitor (IC50s: 4.27 μΜ for hMAO-B, 2.69 μΜ for MB-COMT). hMAO-B/MB-COMT-IN-2 protects cells against oxidative damage. hMAO-B/MB-COMT-IN-2 can be used in the research of neurodegeneration disease, such as Parkinson’s Disease (PD) .
    hMAO-B/MB-COMT-IN-2
  • HY-100642

    Ro 40-7591

    Drug Metabolite COMT Amyloid-β Apoptosis Reactive Oxygen Species (ROS) Neurological Disease Cancer
    3-O-Methyltolcapone (Ro 40-7591) is a metabolite of Tolcapone (HY-17406). Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor with an IC50of 773 nM. Tolcapone can inhibits α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone can cause oxidative stress and induce cancer cells apoptosis and ROS production. Tolcapone can be used for the researches of cancer and neurological disease, such as Parkinson disease and neuroblastoma .
    3-O-Methyltolcapone
  • HY-17406R

    Ro 40-7592 (Standard)

    Reference Standards COMT Amyloid-β Apoptosis Reactive Oxygen Species (ROS) Neurological Disease Cancer
    Tolcapone (Standard) (Ro 40-7592 (Standard)) is the analytical standard of Tolcapone (HY-17406). Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor with an IC50of 773 nM. Tolcapone can inhibits α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone can cause oxidative stress and induce cancer cells apoptosis and ROS production. Tolcapone can be used for the researches of cancer and neurological disease, such as Parkinson disease and neuroblastoma .
    Tolcapone (Standard)
  • HY-17406S1

    Ro 40-7592-d4

    Isotope-Labeled Compounds COMT Amyloid-β Apoptosis Reactive Oxygen Species (ROS) Neurological Disease Cancer
    Tolcapone-d4 (Ro 40-7592-d4) is the deuterium labeled Tolcapone (HY-17406). Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor with an IC50of 773 nM. Tolcapone can inhibits α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone can cause oxidative stress and induce cancer cells apoptosis and ROS production. Tolcapone can be used for the researches of cancer and neurological disease, such as Parkinson disease and neuroblastoma .
    Tolcapone-d4
  • HY-17406S

    Ro 40-7592 d7

    Isotope-Labeled Compounds COMT Amyloid-β Apoptosis Reactive Oxygen Species (ROS) Neurological Disease Cancer
    Tolcapone-d7 (Ro 40-7592-d7) is the deuterium labeled Tolcapone (HY-17406). Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor with an IC50of 773 nM. Tolcapone can inhibits α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone can cause oxidative stress and induce cancer cells apoptosis and ROS production. Tolcapone can be used for the researches of cancer and neurological disease, such as Parkinson disease and neuroblastoma .
    Tolcapone-d7
  • HY-126194

    Ro 61-1448

    Drug Metabolite COMT Amyloid-β Apoptosis Reactive Oxygen Species (ROS) Others
    Tolcapone 3-β-D-glucuronide (Ro 61-1448) is an O-methyl metabolite of Tolcapone (HY-17406) and is pharmacologically inactive. Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor with an IC50of 773 nM. Tolcapone can inhibits α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone can cause oxidative stress and induce cancer cells apoptosis and ROS production. Tolcapone can be used for the researches of cancer and neurological disease, such as Parkinson disease and neuroblastoma .
    Tolcapone 3-β-D-glucuronide
  • HY-162760

    COMT Monoamine Oxidase Neurological Disease
    COMT-IN-1 (compound C12), a nitrophenolic analogue, is an orally active dopamine metabolic enzyme catechol-O-methyltransferase (COMT) inhibitor with IC50s of 0.37 μM, 95.58 μM and 58.82 μM for COMT, MAO-A and MAO-B, respectively. COMT-IN-1 exhibits chelation with a variety of metal ions. COMT-IN-1 exhibits good BBB permeability. COMT-IN-1 improves dopamine levels and ameliorates MPTP (HY-15608)-induced Parkinson's disease (PD) symptoms in mice .
    COMT-IN-1
  • HY-14280A

    COMT Neurological Disease Cancer
    Entacapone sodium salt is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone sodium salt inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone sodium salt is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone sodium salt can be used for the research of Parkinson's disease . Entacapone sodium salt serves as as a inhibit of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders .
    Entacapone sodium salt
  • HY-14280
    Entacapone
    5+ Cited Publications

    COMT Neurological Disease Cancer
    Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 μM). Entacapone can be used for the research of Parkinson's disease . Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders .
    Entacapone
  • HY-100642R

    Ro 40-7591 (Standard)

    Reference Standards Drug Metabolite COMT Amyloid-β Apoptosis Reactive Oxygen Species (ROS) Neurological Disease Cancer
    3-O-Methyltolcapone (Standard) (Ro 40-7591 (Standard)) is the analytical standard of 3-O-Methyltolcapone (HY-174062). 3-O-Methyltolcapone (Ro 40-7591) is a metabolite of Tolcapone (HY-17406). Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor with an IC50of 773 nM. Tolcapone can inhibits α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone can cause oxidative stress and induce cancer cells apoptosis and ROS production. Tolcapone can be used for the researches of cancer and neurological disease, such as Parkinson disease and neuroblastoma .
    3-O-Methyltolcapone (Standard)
  • HY-14280S

    COMT Neurological Disease
    Entacapone-d10 is the deuterium labeled Entacapone. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 μM). Entacapone can be used for the research of Parkinson's disease . Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders .
    Entacapone-d10
  • HY-100642S

    Ro 40-7591 d7

    Isotope-Labeled Compounds Drug Metabolite COMT Amyloid-β Apoptosis Reactive Oxygen Species (ROS) Neurological Disease Cancer
    3-O-Methyltolcapone-d7 (Ro 40-7591 d7) is a deuterium labeled 3-O-Methyltolcapone (HY-174062). 3-O-Methyltolcapone (Ro 40-7591) is a metabolite of Tolcapone (HY-17406). Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor with an IC50of 773 nM. Tolcapone can inhibits α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone can cause oxidative stress and induce cancer cells apoptosis and ROS production. Tolcapone can be used for the researches of cancer and neurological disease, such as Parkinson disease and neuroblastoma .
    3-O-Methyltolcapone-d7
  • HY-14280R

    Reference Standards COMT Neurological Disease Cancer
    Entacapone (Standard) is the analytical standard of Entacapone. This product is intended for research and analytical applications. Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease . Entacapone serves as a inhibitor of FTO demethylation with an IC50 of 3.5 μM, can be used for the research of metabolic disorders .
    Entacapone (Standard)
  • HY-100642S1

    Ro 40-7591-d4

    Isotope-Labeled Compounds Drug Metabolite COMT Amyloid-β Apoptosis Reactive Oxygen Species (ROS) Neurological Disease Cancer
    3-O-Methyltolcapone-d4 (Ro 40-7591 d4) is a deuterium labeled 3-O-Methyltolcapone (HY-174062). 3-O-Methyltolcapone (Ro 40-7591) is a metabolite of Tolcapone (HY-17406). Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor with an IC50of 773 nM. Tolcapone can inhibits α-syn and Aβ42 oligomerization and fibrillogenesis. Tolcapone can cause oxidative stress and induce cancer cells apoptosis and ROS production. Tolcapone can be used for the researches of cancer and neurological disease, such as Parkinson disease and neuroblastoma .
    3-O-Methyltolcapone-d4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: